skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Effect of Amifostine on Response Rates in Locally Advanced Non-Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis

Abstract

Purpose: Amifostine can reduce the cytotoxic effects of chemotherapy and radiotherapy in patients with locally advanced non-small-cell lung cancer, but concerns remain regarding its possible tumor-protective effects. Studies with sufficient statistical power to address this question are lacking. Methods and Materials: We performed a meta-analysis of all published clinical trials involving locally advanced non-small-cell lung cancer patients treated with radiotherapy with or without chemotherapy, who had been randomized to treatment with amifostine vs. no amifostine or placebo. Random effects estimates of the relative risk of overall, partial, and complete response were obtained. Results: Seven randomized trials involving 601 patients were identified. Response rate data were available for six studies (552 patients). The pooled relative risk (RR) estimate was 1.07 (95% confidence interval, 0.97-1.18; p = 0.18), 1.21 (95% confidence interval, 0.83-1.78; p = 0.33), and 0.99 (95% confidence interval, 0.78-1.26; p = 0.95) for overall, complete, and partial response, respectively (a RR >1 indicates improvement in response with amifostine compared with the control arm). The results were similar after sensitivity analyses. No evidence was found of treatment effect heterogeneity across the studies. Conclusions: Amifostine has no effect on tumor response in patients with locally advanced non-small-cell lung cancer treated withmore » radiotherapy with or without chemotherapy.« less

Authors:
 [1];  [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8]
  1. Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL (United States)
  2. Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
  3. Department of Radiation Oncology, Henry Ford Health System, Detroit, MI (United States)
  4. Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA (United States)
  5. Division of Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA (United States)
  6. Department of Radiation Oncology, Metaxa Cancer Hospital, Piraeus (Greece)
  7. Department of Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis (Greece)
  8. Department of Radiation Oncology, University of California, San Diego, School of Medicine, La Jolla, CA (United States)
Publication Date:
OSTI Identifier:
20951621
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 68; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.11.043; PII: S0360-3016(06)03601-7; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; CHEMOTHERAPY; CLINICAL TRIALS; HEALTH HAZARDS; LUNGS; PATIENTS; RADIOTHERAPY; SAFETY; SENSITIVITY ANALYSIS

Citation Formats

Mell, Loren K, Malik, Renuka, Komaki, Ritsuko, Movsas, Benjamin, Swann, R Suzanne, Langer, Corey, Antonadou, Dosia, Koukourakis, Michael, and Mundt, Arno J. Effect of Amifostine on Response Rates in Locally Advanced Non-Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2006.11.043.
Mell, Loren K, Malik, Renuka, Komaki, Ritsuko, Movsas, Benjamin, Swann, R Suzanne, Langer, Corey, Antonadou, Dosia, Koukourakis, Michael, & Mundt, Arno J. Effect of Amifostine on Response Rates in Locally Advanced Non-Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis. United States. https://doi.org/10.1016/j.ijrobp.2006.11.043
Mell, Loren K, Malik, Renuka, Komaki, Ritsuko, Movsas, Benjamin, Swann, R Suzanne, Langer, Corey, Antonadou, Dosia, Koukourakis, Michael, and Mundt, Arno J. 2007. "Effect of Amifostine on Response Rates in Locally Advanced Non-Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis". United States. https://doi.org/10.1016/j.ijrobp.2006.11.043.
@article{osti_20951621,
title = {Effect of Amifostine on Response Rates in Locally Advanced Non-Small-Cell Lung Cancer Patients Treated on Randomized Controlled Trials: A Meta-Analysis},
author = {Mell, Loren K and Malik, Renuka and Komaki, Ritsuko and Movsas, Benjamin and Swann, R Suzanne and Langer, Corey and Antonadou, Dosia and Koukourakis, Michael and Mundt, Arno J},
abstractNote = {Purpose: Amifostine can reduce the cytotoxic effects of chemotherapy and radiotherapy in patients with locally advanced non-small-cell lung cancer, but concerns remain regarding its possible tumor-protective effects. Studies with sufficient statistical power to address this question are lacking. Methods and Materials: We performed a meta-analysis of all published clinical trials involving locally advanced non-small-cell lung cancer patients treated with radiotherapy with or without chemotherapy, who had been randomized to treatment with amifostine vs. no amifostine or placebo. Random effects estimates of the relative risk of overall, partial, and complete response were obtained. Results: Seven randomized trials involving 601 patients were identified. Response rate data were available for six studies (552 patients). The pooled relative risk (RR) estimate was 1.07 (95% confidence interval, 0.97-1.18; p = 0.18), 1.21 (95% confidence interval, 0.83-1.78; p = 0.33), and 0.99 (95% confidence interval, 0.78-1.26; p = 0.95) for overall, complete, and partial response, respectively (a RR >1 indicates improvement in response with amifostine compared with the control arm). The results were similar after sensitivity analyses. No evidence was found of treatment effect heterogeneity across the studies. Conclusions: Amifostine has no effect on tumor response in patients with locally advanced non-small-cell lung cancer treated with radiotherapy with or without chemotherapy.},
doi = {10.1016/j.ijrobp.2006.11.043},
url = {https://www.osti.gov/biblio/20951621}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 1,
volume = 68,
place = {United States},
year = {Tue May 01 00:00:00 EDT 2007},
month = {Tue May 01 00:00:00 EDT 2007}
}